Supplementary Data: Figure S1-3 and Table S1-S5 from Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts
التفاصيل البيبلوغرافية
العنوان:
Supplementary Data: Figure S1-3 and Table S1-S5 from Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts
American Association for Cancer Research (AACR), 2023.
سنة النشر:
2023
الوصف:
Supplemental Figure 1: heavy and light chain sequences for 5F9, the human IgG1 monoclonal antibody (mAb) targeting the extracellular domain of GCC as described previously Supplemental Figure 2: Characterization of TAK-164 and chKTI-DGN549 by A) SDS PAGE gel and B) by Liquid chromatography-mass spectrometry (LC-MS) Supplemental Figure 3: In vivo activity of TAK-164 in PHTXM-46C Supplemental Table 1: Growth rate inhibition following treatment with TAK-164 and B) chKTI-ADC in PHTX and cell derived xenograft models Supplemental Table 2: Growth Rate Inhibition and associated statistics for HEK293 GCC#2 Supplemental Table 3: Growth Rate Inhibition and associated statistics for PHTX-09C Supplemental Table 4: Growth Rate Inhibition and associated statistics for PHTX-17C Supplemental Table 5: Growth Rate Inhibition and associated statistics for PHTX-11C
